Clinical trial
Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage…
NCT00079157 · Abramson Cancer Center at Penn Medicine, Other · Completed
Key facts
| NCT number | NCT00079157 |
|---|---|
| Title | Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer |
| Official title | Phase I Study Of Telomerase Peptide Vaccination For Patients With Advanced Breast Cancer |
| Lead sponsor | Abramson Cancer Center at Penn Medicine, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | incomplete Freund's adjuvant, sargramostim, telomerase: 540-548 peptide vaccine |
| Enrollment | 28 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Mar 10, 2004 |
| Last update posted | Feb 5, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: